v3.26.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Pay vs Performance Disclosure          
Pay vs Performance Disclosure, Table
Value of Initial Fixed
$100 Investment Based on:
Year
(a)		Summary
Compensation
Table Total for
PEO ($)
(b)		Compensation
Actually Paid
to PEO ($) (1)(2)
(c)		Average
Summary
Compensation
Table Total
for Non-PEO
NEOs ($)
(d)		Average
Compensation Actually Paid
to Non-PEO
NEOs ($) (1)(2)
(e)		ImmunityBio
Total
Shareholder
Return ($) (3)
(f)		Peer Group
Total
Shareholder
Return ($) (4)
(g)		Net Loss
($M)
(h)		Revenue
($M)
(i)
2025
12,716,953 6,222,909 5,761,037 2,920,536 14.85 119.92 (351.5)113.3 
2024
10,954,875 4,065,929 5,801,150 2,319,758 19.20 90.58 (413.6)14.7 
2023
1,156,903 262,372 961,711 622,399 37.66 91.84 (583.9)0.6 
2022
4,008,507 2,751,454 2,724,907 2,481,143 38.03 88.53 (417.3)0.2 
2021
29,016,727 10,356,288 2,888,272 1,170,403 45.61 99.37 (349.8)0.9 
        
Named Executive Officers, Footnote As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (SCT), the table below provides a reconciliation of the SCT amounts to the Compensation Actually Paid (CAP) amounts in the Pay Versus Performance table for Mr. Adcock and the average SCT and CAP amounts for our other NEOs for each of the last five years. The other Non-PEO NEOs for 2025 include Mr. Sachs, Dr. Soon-Shiong, and Ms. Lauer. The other Non-PEO NEOs for each of 2024, 2023, 2022, and 2021 include Mr. Sachs and Dr. Soon-Shiong.        
PEO Total Compensation Amount $ 12,716,953 $ 10,954,875 $ 1,156,903 $ 4,008,507 $ 29,016,727
PEO Actually Paid Compensation Amount $ 6,222,909 4,065,929 262,372 2,751,454 10,356,288
Adjustment To PEO Compensation, Footnote As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (SCT), the table below provides a reconciliation of the SCT amounts to the Compensation Actually Paid (CAP) amounts in the Pay Versus Performance table for Mr. Adcock and the average SCT and CAP amounts for our other NEOs for each of the last five years. The other Non-PEO NEOs for 2025 include Mr. Sachs, Dr. Soon-Shiong, and Ms. Lauer. The other Non-PEO NEOs for each of 2024, 2023, 2022, and 2021 include Mr. Sachs and Dr. Soon-Shiong.
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
Required Adjustments to Summary Compensation Table Totals to Determine “Compensation Actually Paid”
Summary
Compensation
Table Total ($)		Summary
Compensation
Table Value
of Stock
Awards ($)		Summary
Compensation
Table Value
of Option
Awards ($)		Fair Value
as of Year
End of
Equity
Awards
Granted
During the
Year ($)		Year-Over-Year
Increase
(Decrease) in
Fair Value as
of Year End
of Unvested
Awards
Granted in
Prior Years ($)		Increase
(Decrease)
From Prior
Year End
in Fair
Value of
Awards That
Vested
During the
Year ($)		Compensation
Actually
Paid ($)
Year(a)(b)(c)(d)(e)(f)(g)=(a)-(b)-(c)
+(d)+(e)+(f)
Richard
   Adcock
2025
12,716,953 2,787,828 8,353,406 4,780,201 (626,555)493,544 6,222,909 
Average
   of Other
   NEOs
2025
5,761,037 1,226,643 3,675,499 2,103,288 (216,284)174,637 2,920,536 
        
Non-PEO NEO Average Total Compensation Amount $ 5,761,037 5,801,150 961,711 2,724,907 2,888,272
Non-PEO NEO Average Compensation Actually Paid Amount $ 2,920,536 2,319,758 622,399 2,481,143 1,170,403
Adjustment to Non-PEO NEO Compensation Footnote As the valuation methods for “compensation actually paid” required by the SEC differ from those required in the Summary Compensation Table (SCT), the table below provides a reconciliation of the SCT amounts to the Compensation Actually Paid (CAP) amounts in the Pay Versus Performance table for Mr. Adcock and the average SCT and CAP amounts for our other NEOs for each of the last five years. The other Non-PEO NEOs for 2025 include Mr. Sachs, Dr. Soon-Shiong, and Ms. Lauer. The other Non-PEO NEOs for each of 2024, 2023, 2022, and 2021 include Mr. Sachs and Dr. Soon-Shiong.
Summary Compensation Table to Compensation Actually Paid Reconciliation Table
Required Adjustments to Summary Compensation Table Totals to Determine “Compensation Actually Paid”
Summary
Compensation
Table Total ($)		Summary
Compensation
Table Value
of Stock
Awards ($)		Summary
Compensation
Table Value
of Option
Awards ($)		Fair Value
as of Year
End of
Equity
Awards
Granted
During the
Year ($)		Year-Over-Year
Increase
(Decrease) in
Fair Value as
of Year End
of Unvested
Awards
Granted in
Prior Years ($)		Increase
(Decrease)
From Prior
Year End
in Fair
Value of
Awards That
Vested
During the
Year ($)		Compensation
Actually
Paid ($)
Year(a)(b)(c)(d)(e)(f)(g)=(a)-(b)-(c)
+(d)+(e)+(f)
Richard
   Adcock
2025
12,716,953 2,787,828 8,353,406 4,780,201 (626,555)493,544 6,222,909 
Average
   of Other
   NEOs
2025
5,761,037 1,226,643 3,675,499 2,103,288 (216,284)174,637 2,920,536 
        
Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid Compared to Total Shareholder Return
1649267442276
        
Compensation Actually Paid vs. Net Income Compensation Actually Paid Compared to Net Loss
1649267442330
        
Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid Compared to Revenue
1649267442383
        
Total Shareholder Return Vs Peer Group Compensation Actually Paid Compared to Total Shareholder Return
1649267442276
        
Tabular List, Table
Pursuant to Item 402(v) of Regulation S-K, the Compensation Committee identified the following Financial and Commercial performance measures used in our STIP and LTIP programs as representing the performance measures used to link “compensation actually paid” in 2025 to the company’s performance:
•Revenue
•Adjusted EBITDA
•Clinical Development Goals (1)
_______________
(1)The Clinical Development goals are an operational metric, not a financial performance measure.
        
Total Shareholder Return Amount $ 14.85 19.20 37.66 38.03 45.61
Peer Group Total Shareholder Return Amount 119.92 90.58 91.84 88.53 99.37
Net Income (Loss) $ (351,500,000) $ (413,600,000) $ (583,900,000) $ (417,300,000) $ (349,800,000)
Company Selected Measure Amount 113,300,000 14,700,000 600,000 200,000 900,000
PEO Name Richard    Adcock        
Additional 402(v) Disclosure The fair value or change in fair value, as applicable, of equity awards was determined in accordance with ASC 718 by reference to (1) for RSU awards, the closing price of our common stock on the applicable measurement date and (2) for option awards, a Black-Scholes valuation model with updated assumptions for time to expiration, closing price of our common stock, volatility, and risk-free rate as of the applicable measurement date.
(3)Pursuant to SEC rules, TSR reflects an initial investment of $100 in the company’s common stock on December 31, 2021. Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period (December 31, 2021 – December 31, 2025), assuming dividend reinvestment, and the difference between the share price at the end and the beginning of the measurement period by the share price at the beginning of the measurement period. The company has never paid cash dividends on its common stock.
(4)Peer Group TSR reflects an initial investment of $100 in the Nasdaq Biotechnology Index on December 31, 2021, which is the same index we used in the Stock Performance Graph in our Annual Report. Cumulative TSR is calculated by dividing the sum of the cumulative amount of dividends for the measurement period (December 31, 2021 – December 31, 2025), assuming dividend reinvestment, and the difference between the share price at the end and the beginning of the measurement period by the share price at the beginning of the measurement period. 		       
Measure:: 1          
Pay vs Performance Disclosure          
Name Revenue        
Measure:: 2          
Pay vs Performance Disclosure          
Name Adjusted EBITDA        
Measure:: 3          
Pay vs Performance Disclosure          
Name Clinical Development Goals        
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ 4,780,201        
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (626,555)        
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 493,544        
PEO | Summary Compensation Table Value of Stock Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (2,787,828)        
PEO | Summary Compensation Table Value of Option Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (8,353,406)        
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 2,103,288        
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (216,284)        
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount 174,637        
Non-PEO NEO | Summary Compensation Table Value of Stock Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount (1,226,643)        
Non-PEO NEO | Summary Compensation Table Value of Option Awards [Member]          
Pay vs Performance Disclosure          
Adjustment to Compensation, Amount $ (3,675,499)